HK1256423A1 - 纤维化治疗 - Google Patents

纤维化治疗 Download PDF

Info

Publication number
HK1256423A1
HK1256423A1 HK18115556.4A HK18115556A HK1256423A1 HK 1256423 A1 HK1256423 A1 HK 1256423A1 HK 18115556 A HK18115556 A HK 18115556A HK 1256423 A1 HK1256423 A1 HK 1256423A1
Authority
HK
Hong Kong
Prior art keywords
treatment
fibrosis
kits
compositions
methods
Prior art date
Application number
HK18115556.4A
Other languages
English (en)
Chinese (zh)
Inventor
Siew Yeen Chai
Robert Widdop
Tracey Gaspari
Huey Wen LEE
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903035A external-priority patent/AU2015903035A0/en
Application filed by Monash University filed Critical Monash University
Publication of HK1256423A1 publication Critical patent/HK1256423A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
HK18115556.4A 2015-07-30 2016-07-29 纤维化治疗 HK1256423A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903035 2015-07-30
AU2015903035A AU2015903035A0 (en) 2015-07-30 Fibrotic treatment
PCT/AU2016/050681 WO2017015720A1 (en) 2015-07-30 2016-07-29 Fibrotic treatment

Publications (1)

Publication Number Publication Date
HK1256423A1 true HK1256423A1 (zh) 2019-09-20

Family

ID=57883919

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115556.4A HK1256423A1 (zh) 2015-07-30 2016-07-29 纤维化治疗

Country Status (8)

Country Link
US (5) US10100311B2 (cg-RX-API-DMAC7.html)
EP (1) EP3328384B1 (cg-RX-API-DMAC7.html)
JP (3) JP2018527330A (cg-RX-API-DMAC7.html)
AU (1) AU2016301113B2 (cg-RX-API-DMAC7.html)
CA (1) CA3017028C (cg-RX-API-DMAC7.html)
HK (1) HK1256423A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201808478RA (cg-RX-API-DMAC7.html)
WO (1) WO2017015720A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11306066B2 (en) * 2015-05-08 2022-04-19 Monash University 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors
WO2017015720A1 (en) * 2015-07-30 2017-02-02 Monash University Fibrotic treatment
CN111163793A (zh) * 2017-07-17 2020-05-15 莫纳什大学 血管紧张素受体激动剂及其用途
JP2022516611A (ja) * 2018-12-28 2022-03-01 ザ ジェネラル ホスピタル コーポレイション 線維性疾患の治療のための抗エフリン-b2遮断抗体
WO2021050089A1 (en) * 2019-09-09 2021-03-18 Washington State University Genetic test for identifying cats at a high risk for developing tubulointerstitial fibrosis
TW202143994A (zh) 2020-02-19 2021-12-01 美商希皮恩製藥公司 環孢素類似物於治療纖維化之用途
WO2023099589A1 (en) * 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Irap inhibitors for use in the treatment of inflammatory diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579768A1 (en) * 2004-09-09 2006-03-16 Howard Florey Institute Of Experimental Physiology And Medicine Enzyme inhibitors and uses thereof
BRPI0615439A2 (pt) * 2005-08-23 2011-05-17 Wyeth Corp métodos para o tratamento de ansiedade e para identificação de agentes ansiolìticos
US8263775B2 (en) * 2007-11-19 2012-09-11 Howard Florey Institute Insulin-regulated aminopeptidase (IRAP) inhibitors and uses thereof
JP2015504870A (ja) * 2011-12-16 2015-02-16 タリックス ファーマシューティカルズ リミテッド 線維症を処置するためのアンジオテンシン
CA2861521A1 (en) * 2012-02-06 2013-08-15 Glaxosmithkline Intellectual Property (No.2) Limited Novel use
JP6327923B2 (ja) 2014-04-25 2018-05-23 旭化成株式会社 ポリアセタール樹脂組成物、及びそれからなる成形体
DE102014114090A1 (de) 2014-09-29 2016-03-31 Karlsruher Institut für Technologie Verfahren zur Abtrennung von Aluminium bei der Calciumsilikatproduktion
US9519061B2 (en) * 2014-12-26 2016-12-13 Here Global B.V. Geometric fingerprinting for localization of a device
US11306066B2 (en) * 2015-05-08 2022-04-19 Monash University 4H-pyran compounds as insulin-regulated aminopeptidase (IRAP) inhibitors
WO2017015720A1 (en) * 2015-07-30 2017-02-02 Monash University Fibrotic treatment

Also Published As

Publication number Publication date
US20200362354A1 (en) 2020-11-19
JP2020189845A (ja) 2020-11-26
EP3328384A4 (en) 2019-03-06
EP3328384A1 (en) 2018-06-06
SG11201808478RA (en) 2018-10-30
CA3017028A1 (en) 2017-02-02
US10787668B2 (en) 2020-09-29
US20190249179A1 (en) 2019-08-15
US10100311B2 (en) 2018-10-16
US11078488B2 (en) 2021-08-03
JP7457360B2 (ja) 2024-03-28
US11834663B2 (en) 2023-12-05
WO2017015720A1 (en) 2017-02-02
JP2023030022A (ja) 2023-03-07
US20210340547A1 (en) 2021-11-04
US20240084308A1 (en) 2024-03-14
JP2018527330A (ja) 2018-09-20
US20180223287A1 (en) 2018-08-09
AU2016301113A1 (en) 2018-02-22
AU2016301113B2 (en) 2019-10-03
EP3328384B1 (en) 2020-07-29
CA3017028C (en) 2020-06-16

Similar Documents

Publication Publication Date Title
EP3556858A3 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
WO2014152012A3 (en) Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
HK1252542A1 (zh) 改进的尿酸酶序列和治疗方法
EP3169336A4 (en) Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
EP3207940A4 (en) Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
WO2015120372A3 (en) Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
WO2015179823A3 (en) Lung localized inhibitors of alpha(v)beta 6
WO2016205323A8 (en) Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
PH12017501980A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
EP3389620A4 (en) Stem cell stimulating compositions and methods of treating melasma
HK1257171A1 (zh) 间变性淋巴瘤激酶(alk)和丝氨酸富集蛋白激酶 (sppk)的抑制剂及其使用方法
IL290983A (en) Treatment methods
WO2015156674A3 (en) Method for treating cancer
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
IL287250A (en) treatment method
HK1244692A1 (zh) 治疗纤维化的方法
HK1255221A1 (zh) 使用卡多曲组合物进行治疗的方法
IL254899A0 (en) Preparations and methods for treating and/or preventing necrosis of a cell or tissue specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes
CA2986376C (en) Poxvirus-derived promoter, and vector comprising same
WO2017005646A8 (en) Methods and pharmaceutical compositions for the treatment of cystic fibrosis
GB201918853D0 (en) Methods of treatment
WO2016135456A3 (en) A gm-csf negative modulator for use in treating, preventing or ameliorating aortopathy
EP3706781A4 (en) METHODS OF TREATMENT AND PROTECTION AGAINST HEART DISEASE, CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS AND SYMPTOMS
EP3601565A4 (en) MIR-92 INHIBITORS IN THE TREATMENT OF HEART FAILURE